Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: Differences between stopping and continuing the antiresorptive agent

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 10, 2009, Pages 3772-3780

  Cosman, Felicia ^a,b   Wermers, Robert A ^c   Recknor, Christopher ^d   Mauck, Karen F ^c   Xie, Li ^e   Glass, Emmett V ^e   Krege, John H ^e  

^a HELEN HAYES HOSPITAL   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c MAYO CLINIC   (United States)

^d United Osteoporosis Centers   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; THYROTROPIN;

ADD ON THERAPY; ADULT; ARTICLE; BACKACHE; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DIZZINESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FOLLOW UP; HEADACHE; HEART PALPITATION; HIP; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERTENSION; LARGE CELL CARCINOMA; LEG PAIN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MIGRAINE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYNCOPE; THORAX PAIN; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 70349897684     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-2719     Document Type: Article

References (20)

1. Lindsay R, Cosman F, Zhou H, Bostrom MP, Shen VW, Cruz JD, Nieves JW, DempsterDW2006 A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 21:366-373
2. Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB 2007 Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 22:495-502 (Pubitemid 47457425)
3. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762-1768 (Pubitemid 41138965)
4. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441 (Pubitemid 32402100)
5. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555 (Pubitemid 27348431)
6. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF 2003 Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932-1941 (Pubitemid 37377441)
7. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetiæ K, Müller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846-1853 (Pubitemid 32911491)
8. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349: 1207-1215 (Pubitemid 37152030)
9. Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH 2005 Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20:1905-1911 (Pubitemid 41532775)
10. Ettinger B, San Martin J, Crans G, Pavo I 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745-751 (Pubitemid 41094385)
11. Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP 2008 Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785-3793
12. Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV 2008 Effects of prior antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852-860
13. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R 2005 Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353:566-575 (Pubitemid 41138938)
14. Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R 2008 Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int 19:529-535
15. Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R 2001 Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16: 925-931 (Pubitemid 32332303)
16. Wermers RA, Recknor CP, Cosman F, Xie L, Glass EV, Krege JH 2008 Effects of teriparatide on serum calcium in postmenopausal womenwith osteoporosis previously treated with raloxifene or alendronate. Osteoporos Int 19:1055-1065
17. Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R 2003 Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 88:1150-1156 (Pubitemid 36337769)
18. Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA 2007 The effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT exams. J Bone Miner Res 22:149-157
19. Glover SJ, Gall M, Schoenborn-Kellenberger O, Wagener M, Garnero P, Boonen S, Cauley JA, Black DM, Delmas PD, Eastell R 2009 Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 24:389-397
20. Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R 2008 Establishing reference range for bone turnover markers in young, healthy women. Bone 42:623-630